Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein


GTO ID GTC2784
Trial ID NCT05037097
Disease COVID-19 | Coronavirus Infectious Disease
Altered gene VEEV|S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment ARCT-154|COVID-19 mRNA vaccine, Arcturus;ARCT-165;ARCT-021
Location approved Japan;NULL;NULL
PhasePhase1|Phase2
Recruitment statusUnknown
TitleA Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2
Year2021
CountryUnited States|Singapore
Company sponsorArcturus Therapeutics, Inc.
Other ID(s)ARCT-165-01
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: ARCT-165_two doses
Administration route None
Dosage ARCT-165, one dose on Day 1 and one dose on Day 29
Age Adult, Older_Adult
Cohort2: ARCT-154_two doses
Administration route None
Dosage ARCT-154, one dose on Day 1 and one dose on Day 29
Age Adult, Older_Adult
Cohort3: ARCT-021_two doses
Administration route None
Dosage ARCT-021, one dose on Day 1 and one dose on Day 29
Age Adult, Older_Adult
Cohort4: ARCT-165_one dose
Administration route None
Dosage ARCT-165, one dose on Day 1
Age Adult, Older_Adult
Cohort5: ARCT-154_one dose
Administration route None
Dosage ARCT-154, one dose on Day 1
Age Adult, Older_Adult
Cohort6: ARCT-021_one dose
Administration route None
Dosage ARCT-021, one dose on Day 1
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph